India, April 24 -- Gain Therapeutics, Inc. (GANX) will deliver an oral presentation next month highlighting new updates on its lead Parkinson's disease candidate, GT-02287.
The presentation will take place at the 3rd International GBA1 Meeting 2026 on May 22 in Phoenix, Arizona. Jonas Hannestad, M.D., Ph.D., the company's CMO, will present "An update on the development of the GCase modulator GT-02287 for Parkinson's disease" during a session focused on ongoing preclinical and clinical programs.
GT-02287 is an orally administered, brain-penetrant small molecule designed to restore the function of glucocerebrosidase (GCase)- an enzyme impaired in people with GBA1-associated and idiopathic Parkinson's disease. In preclinical studies, the the...